Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer

Drug Metabolism Reviews

Volumn 47, Issue 2, 2015, Pages 199-221

  Beyerle, Jolantha ^a   Frei, Eva ^a   Stiborova, Marie ^b   Habermann, Nina ^a   Ulrich, Cornelia M ^a,c,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c USA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Biotransformation; Colorectal cancer; Cytochrome P450; Glutathione S transferase; UDP glucuronosyltransferase

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2F1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A43; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; GLUTATHIONE TRANSFERASE A3; GLUTATHIONE TRANSFERASE A4; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M2; SULFOTRANSFERASE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; ARYLAMINE ACETYLTRANSFERASE;

BIOTRANSFORMATION; CANCER RISK; COLON; COLORECTAL CANCER; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; PHENOTYPE; PROTEIN EXPRESSION; RECTUM; REVIEW; XENOBIOTIC METABOLISM; COLORECTAL TUMOR; ENZYMOLOGY; GENETICS; METABOLISM;

ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; COLON; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; RECTUM; SULFOTRANSFERASES; XENOBIOTICS;

EID: 84932142020     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.996649     Document Type: Review

References (296)

1. Adler V, Yin Z, Fuchs SY, et al. (1999). Regulation of JNK signaling by GSTp. EMBO J 18:1321-1334.
2. Ananthakrishnan AN, Du M, Berndt SI, et al. (2014). Red meat intake, NAT2, and risk of colorectal cancer: A pooled analysis of 11 studies. Cancer Epidemiol Biomarkers Prev 24:198-205.
3. Andersson T, Regardh CG, Lou YC, et al. (1992). Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2:25-31.
4. Androutsopoulos VP, Spyrou I, Ploumidis A, et al. (2013). Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS One 8:e82487.
5. Angstadt AY, Berg A, Zhu J, et al. (2013). The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk. Cancer 119:2477-2485.
6. Angstadt AY, Hartman TJ, Lesko SM, et al. (2014). The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene-environment interactions. Genes Chromosomes Cancer 53:454-466.
7. Badal S, Delgoda R. (2013). CYP1B1: Friend or foe?. A critical review. OA Biochemistry 1:8.
8. Badal S, Shields M, Delgoda R. (2012). Cytochrome P450 enzyme inhibitors from nature. In: Sharma PR, ed. Enzyme inhibition and bioapplications. Rijeka, Croatia: InTech, 39-56.
9. Baldwin RM, Shultz MA, Buckpitt AR. (2005). Bioactivation of the pulmonary toxicants naphthalene and 1-nitronaphthalene by rat CYP2F4. J Pharmacol Exp Ther 312:857-865.
10. Bamber DE, Fryer AA, Strange RC, et al. (2001). Phenol sulphotransferase SULT1A11 genotype is associated with reduced risk of colorectal cancer. Pharmacogenetics 11:679-685.
11. Barrett JH, Smith G, Waxman R, et al. (2003). Investigation of interaction between N-Acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis 24: 275-282.
12. Basu NK, Kubota S, Meselhy MR, et al. (2004). Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem 279:28320-28329.
13. Bedford MR, Anathhanam S, Saleh D, et al. (2012). Response of glutathione S-Transferase Pi (GSTP1) to neoadjuvant therapy in rectal adenocarcinoma. Colorectal Dis 14:1483-1488.
14. Bell DA, Taylor JA, Paulson DF, et al. (1993). Genetic risk and carcinogen exposure: A common inherited defect of the carcinogenmetabolism gene glutathione S-Transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159-1164.
15. Bergheim I, Bode C, Parlesak A. (2005). Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol 5:34.
16. Bergheim I, Bode C, Parlesak A. (2005). Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 5:4.
17. Bernard O, Guillemette C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
18. Beverage JN, Sissung TM, Sion AM, et al. (2007). CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 96: 2224-2231.
19. Bhasker CR, Mckinnon W, Stone A, et al. (2000). Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
20. Bigler J, Whitton J, Lampe JW, et al. (2001). CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 61:3566-3569.
21. Bingham SA, Day NE, Luben R, et al. (2003). Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study. Lancet 361:1496-1501.
22. Board PG. (1998). Identification of cDNAs encoding two human alpha class glutathione transferases (GSTA3 and GSTA4) and the heterologous expression of GSTA4-4. Biochem J 330:827-831.
23. Bogaards JJ, Verhagen H, Willems MI, et al. (1994). Consumption of Brussels sprouts results in elevated alpha-class glutathione S-Transferase levels in human blood plasma. Carcinogenesis 15: 1073-1075.
24. Boukouvala S, Fakis G. (2005). Arylamine N-Acetyltransferases: What we learn from genes and genomes. Drug Metab Rev 37:511-564.
25. Burchell B, Hume R. (1999). Molecular genetic basis of Gilberts syndrome. J Gastroenterol Hepatol 14:960-966.
26. Buters J, Quintanilla-Martinez L, Schober W, et al. (2003). CYP1B1 determines susceptibility to low doses of 7, 12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: Correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis 24: 327-334.
27. Butler LM, Duguay Y, Millikan RC, et al. (2005). Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:1626-1232.
28. Carlini LE, Meropol NJ, Bever J, et al. (2005). UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: 1226-1236.
29. Carr BA, Wan J, Hines RN, Yost GS. (2003). Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif. J Biol Chem 278:15473-15483.
30. Chan AT, Hsu M, Zauber AG, et al. (2012). The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila) 5:61-72.
31. Chan AT, Tranah GJ, Giovannucci EL, et al. (2005). Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 97:457-460.
32. Chan AT, Tranah GJ, Giovannucci EL, et al. (2005). Prospective study of N-Acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer. Int J Cancer 115:648-652.
33. Chang H, Su JM, Huang CC, et al. (2005). Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detect Prev 29:562-569.
34. Chen J, Stampfer MJ, Hough HL, et al. (1998). A prospective study of N-Acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 58:3307-3311.
35. Chen K, Jiang QT, He HQ. (2005). Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol 11:331-335.
36. Chen N, Whitehead SE, Caillat AW, et al. (2002). Identification and cross-species comparisons of CYP2F subfamily genes in mammals. Mutat Res 499:155-161.
37. Chia WK, Ali R, Toh HC. (2012). Aspirin as adjuvant therapy for colorectal cancer-Reinterpreting paradigms. Nat Rev Clin Oncol 9: 561-570.
38. Chou HC, Lang NP, Kadlubar FF. (1995). Metabolic activation of Nhydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res 55:525-529.
39. Ciotti M, Marrone A, Potter C, Owens IS. (1997). Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: Pharmacological implications. Pharmacogenetics 7:485-495.
40. Clapper ML, Hoffman SJ, Tew KD. (1991). Glutathione S-Transferases in normal and malignant human colon tissue. Biochim Biophys Acta 1096:209-216.
41. Clapper ML, Szarka CE, Pfeiffer GR, et al. (1997). Preclinical and clinical evaluation of broccoli supplements as inducers of glutathione S-Transferase activity. Clin Cancer Res 3:25-30.
42. Coffman BL, Rios GR, King CD, Tephly TR. (1997). Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
43. Coles BF, Anderson KE, Doerge DR, et al. (2000). Quantitative analysis of interindividual variation of glutathione S-Transferase expression in human pancreas and the ambiguity of correlating genotype with phenotype. Cancer Res 60:573-579.
44. Coles BF, Chen G, Kadlubar FF, Radominska-Pandya A. (2002). Interindividual variation and organ-specific patterns of glutathione Stransferase alpha, mu, and pi expression in gastrointestinal tract mucosa of normal individuals. Arch Biochem Biophys 403:270-276.
45. Coles BF, Kadlubar FF. (2005). Human alpha class glutathione S-Transferases: Genetic polymorphism, expression, and susceptibility to disease. Methods Enzymol 401:9-42.
46. Coles BF, Morel F, Rauch C, et al. (2001). Effect of polymorphism in the human glutathione S-Transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11:663-669.
47. Court MH, Duan SX, Von Moltke LL, et al. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
48. Court MH, Zhang X, Ding X, et al. (2012). Quantitative distribution of mRNAs encoding the 19 human UDPglucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266-277.
49. Cross JT, Poole EM, Ulrich CM. (2008). A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J 8:237-247.
50. Da Silva TD, Felipe AV, De Lima JM, et al. (2011). N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer. World J Gastroenterol 17:760-765.
51. Dai D, Zeldin DC, Blaisdell JA, et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
52. Daly AK. (1995). Molecular basis of polymorphic drug metabolism. J Mol Med (Berl) 73:539-553.
53. Dang DT, Chen F, Kohli M, et al. (2005). Glutathione S-Transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 65:9485-9494.
54. De Jong MM, Nolte IM, Te Meerman GJ, et al. (2002). Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11:1332-1352.
55. De Kok TM, Van Maanen JM. (2000). Evaluation of fecal mutagenicity and colorectal cancer risk. Mutat Res 463:53-101.
56. De Waziers I, Cugnenc PH, Berger A, et al. (1991). Drug-metabolizing enzyme expression in human normal, peritumoral and tumoral colorectal tissue samples. Carcinogenesis 12:905-909.
57. Dellinger RW, Chen G, Blevins-Primeau AS, et al. (2007). Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 28:2412-2418.
58. Dellinger RW, Fang JL, Chen G, et al. (2006). Importance of UDPglucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: Decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 34: 943-949.
59. Delozier TC, Kissling GE, Coulter SJ, et al. (2007). Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688.
60. Denson J, Xi Z, Wu Y, et al. (2006). Screening for inter-individual splicing differences in human GSTM4 and the discovery of a single nucleotide substitution related to the tandem skipping of two exons. Gene 379:148-155.
61. Desmots F, Rissel M, Loyer P, et al. (2001). Immunohistological analysis of glutathione transferase A4 distribution in several human tissues using a specific polyclonal antibody. J Histochem Cytochem 49: 1573-1580.
62. Dey A. (2013). Cytochrome P450 2E1: Its clinical aspects and a brief perspective on the current research scenario. Subcell Biochem 67: 1-104.
63. Din FV, Theodoratou E, Farrington SM, et al. (2010). Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59: 1670-1679.
64. Ding X, Kaminsky LS. (2003). Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
65. Dogru-Abbasoglu S, Mutlu-Turkoglu U, Turkoglu S, et al. (2002). Glutathione S-Transferase-pi in malignant tissues and plasma of human colorectal and gastric cancers. J Cancer Res Clin Oncol 128: 91-95.
66. Doloff JC, Su T, Waxman DJ. (2010). Adenoviral delivery of pancaspase inhibitor p35 enhances bystander killing by P450 genedirected enzyme prodrug therapy using cyclophosphamide+. BMC Cancer 10:487.
67. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. (2001). cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392.
68. Dulik DM, Fenselau C, Hilton J. (1986). Characterization of melphalanglutathione adducts whose formation is catalyzed by glutathione transferases. Biochem Pharmacol 35:3405-3409.
69. Ebert MN, Klinder A, Peters WH, et al. (2003). Expression of glutathione S-Transferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate. Carcinogenesis 24:1637-1644.
70. Economopoulos KP, Sergentanis TN. (2010). GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: A comprehensive meta-Analysis. Eur J Cancer 46:1617-1631.
71. Edler D, Stenstedt K, Ohrling K, et al. (2009). The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer-A pilot study. Eur J Cancer 45: 705-712.
72. Eimoto H, Tsutsumi M, Nakajima A, et al. (1988). Expression of the glutathione S-Transferase placental form in human lung carcinomas. Carcinogenesis 9:2325-2327.
73. Evans WE, Relling MV. (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491.
74. Fernandez-Salguero P, Gonzalez FJ. (1995). The CYP2A gene subfamily: Species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5: S123-S128.
75. Fernandez-Salguero P, Hoffman SM, Cholerton S, et al. (1995). A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651-660.
76. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
77. Flossmann E, Rothwell PM, British Doctors Aspirin Trial, The UK-TIA Aspirin Trial. (2007). Effect of aspirin on long-Term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369:1603-1613.
78. Fontana RJ, Lown KS, Paine MF, et al. (1999). Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 117:89-98.
79. Fuchs C, Mitchell EP, Hoff PM. (2006). Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 32:491-503.
80. Gaitanarou E, Seretis E, Xinopoulos D, et al. (2008). Immunohistochemical localization of glutathione S-Transferase-pi in human colorectal polyps. World J Gastroenterol 14:4179-4184.
81. Gallagher CJ, Muscat JE, Hicks AN, et al. (2007). The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: Sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 16:823-828.
82. Gaudiano G, Koch TH, Lo Bello M, et al. (2000). Lack of glutathione conjugation to adriamycin in human breast cancer MCF-7/DOX cells. Inhibition of glutathione S-Transferase p1-1 by glutathione conjugates from anthracyclines. Biochem Pharmacol 60:1915-1923.
83. Gervot L, Carriere V, Costet P, et al. (1996). CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ Toxicol Pharmacol 2:381-388.
84. Gervot L, Rochat B, Gautier JC, et al. (1999). Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 9: 295-306.
85. Gibson G, Skett P. (2001). Introduction to drug metabolism. Cheltenham UK: Nelson Thornes Ltd.
86. Gibson P, Gill JH, Khan PA, et al. (2003). Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: Implications for drug development. Mol Cancer Ther 2:527-534.
87. Girard H, Butler LM, Villeneuve L, et al. (2008). UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res 644:56-63.
88. Girard H, Court MH, Bernard O, et al. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515.
89. Giuliani L, Ciotti M, Stoppacciaro A, et al. (2005). UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13:185-191.
90. Goetz MP, Rae JM, Suman VJ, et al. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318.
91. Goldstein JA. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
92. Goldstein JA, De Morais SM. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299.
93. Gomez A, Karlgren M, Edler D, et al. (2007). Expression of CYP2W1 in colon tumors: Regulation by gene methylation. Pharmacogenomics 8: 1315-1325.
94. Gong QH, Cho JW, Huang T, et al. (2001). Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357-368.
95. Gonzalez FJ, Gelboin HV. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183.
96. Green MD, Oturu EM, Tephly TR. (1994). Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos 22:799-805.
97. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354-363.
98. Grubben MJ, Nagengast FM, Katan MB, Peters WHM. (2001). The glutathione biotransformation system and colorectal cancer risk in humans. Scand J Gastroenterol 36:68-76.
99. Grubben MJ, Van Den Braak CC, Broekhuizen R, et al. (2000). The effect of unfiltered coffee on potential biomarkers for colonic cancer risk in healthy volunteers: A randomized trial. Aliment Pharmacol Ther 14:1181-1190.
100. Grubben MJ, Van Den Braak CC, Nagengast FM, Peters WH. (2006). Low colonic glutathione detoxification capacity in patients at risk for colon cancer. Eur J Clin Invest 36:188-192.
101. Grubben MJ, Van Den Braak CC, Peters WH, et al. (2000). Low levels of colonic glutathione S-Transferase in patients with X-linked agammaglobulinaemia. Eur J Clin Invest 30:642-645.
102. Guengerich FP. (2003). Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
103. Guengerich FP, Tang Z, Salamanca-Pinzon SG, Cheng Q. (2010). Characterizing proteins of unknown function: Orphan cytochrome p450 enzymes as a paradigm. Mol Interv 10:153-163.
104. Guillemette C, Levesque E, Harvey M, et al. (2010). UGT genomic diversity: Beyond gene duplication. Drug Metab Rev 42:24-44.
105. Hamada K, Umemoto A, Kajikawa A, et al. (1994). Mucosa-specific DNA adducts in human small intestine: A comparison with the colon. Carcinogenesis 15:2677-2680.
106. Hanioka N, Naito T, Narimatsu S. (2008). Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 74:33-36.
107. Harding D, Fournel-Gigleux S, Jackson MR, Burchell B. (1988). Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci USA 85: 8381-8385.
108. Harris RM, Picton R, Singh S, Waring RH. (2000). Activity of phenolsulfotransferases in the human gastrointestinal tract. Life Sci 67:2051-2057.
109. Harrison DJ, Kharbanda R, Bishop D, et al. (1989). Glutathione S-Transferase isoenzymes in human renal carcinoma demonstrated by immunohistochemistry. Carcinogenesis 10:1257-1260.
110. Hayes JD, Flanagan JU, Jowsey IR. (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88.
111. Hayes JD, Pulford DJ. (1995). The glutathione S-Transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600.
112. Hengstler JG, Bottger T, Tanner B, et al. (1998). Resistance factors in colon cancer tissue and the adjacent normal colon tissue: Glutathione S-Transferases alpha and pi, glutathione and aldehyde dehydrogenase. Cancer Lett 128:105-112.
113. Hoensch H, Morgenstern I, Petereit G, et al. (2002). Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut 50:235-240.
114. Hoensch H, Peters WH, Roelofs HM, Kirch W. (2006). Expression of the glutathione enzyme system of human colon mucosa by localisation, gender and age. Curr Med Res Opin 22:1075-1083.
115. Hoensch HP, Roelofs HM, Edler L, et al. (2013). Disparities of conjugating protective enzyme activities in the colon of patients with adenomas and carcinomas. World J Gastroenterol 19:6020-6025.
116. Hofmann MH, Blievernicht JK, Klein K, et al. (2008). Aberrant splicing caused by single nucleotide polymorphism c.516G4T [Q172H], a marker of CYP2B66, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284-292.
117. Holthe M, Klepstad P, Zahlsen K, et al. (2002). Morphine glucuronideto-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A128 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353-356.
118. Horton JK, Roy G, Piper JT, et al. (1999). Characterization of a chlorambucil-resistant human ovarian carcinoma cell line overexpressing glutathione S-Transferase mu. Biochem Pharmacol 58:693-702.
119. Houlston RS, Tomlinson IP. (2001). Polymorphisms and colorectal tumor risk. Gastroenterology 121:282-301.
120. Howie AF, Forrester LM, Glancey MJ, et al. (1990). Glutathione S-Transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 11:451-458.
121. Huang YH, Galijatovic A, Nguyen N, et al. (2002). Identification and functional characterization of UDP-glucuronosyltransferases UGT1A81, UGT1A82 and UGT1A83. Pharmacogenetics 12: 287-297.
122. Hubatsch I, Ridderstrom M, Mannervik B. (1998). Human glutathione transferase A4-4: An alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem J 330:175-179.
123. Husain A, Zhang X, Doll MA, et al. (2007). Identification of N-Acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35: 721-777.
124. Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
125. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
126. Ishikawa T. Ali-Osman F. 1993. Glutathione-Associated cisdiamminedichloroplatinum II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125.
127. Jaitovitch-Groisman I, Fotouhi-Ardakani N, Schecter RL, et al. (2000). Modulation of glutathione S-Transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz. J Biol Chem 275:33395-33403.
128. Jakobsson J, Ekstrom L, Inotsume N, et al. (2006). Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 91:687-693.
129. Jiang JG, Chen CL, Card JW, et al. (2005). Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707-4715.
130. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. (1993). Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acidcontaining drugs. J Pharmacol Exp Ther 264:475-479.
131. Jin CJ, Miners JO, Burchell B, Mackenzie PI. (1993). The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-Acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis 14:2637-2639.
132. Jinno H, Tanaka-Kagawa T, Ohno A, et al. (2003). Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398-403.
133. Johansson AS, Mannervik B. (2001). Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem 276: 33061-33065.
134. Johnson CM, Wei C, Ensor JE, et al. (2013). Meta-Analyses of colorectal cancer risk factors. Cancer Causes Control 24:1207-1222.
135. Jordan VC. (1982). Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance. Breast Cancer Res Treat 2:123-138.
136. Jordan VC. (1993). Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507-517.
137. Jordan VC, Collins MM, Rowsby L, Prestwich G. (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316.
138. Kantor RR, Giardina SL, Bartolazzi A, et al. (1991). Monoclonal antibodies to glutathione S-Transferase pi-immunohistochemical analysis of human tissues and cancers. Int J Cancer 47:193-201.
139. Karlgren M, Gomez A, Stark K, et al. (2006). Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 341:451-458.
140. Katoh T, Yamano Y, Tsuji M, Watanabe M. (2008). Genetic polymorphisms of human cytosol glutathione S-Transferases and prostate cancer. Pharmacogenomics 9:93-104.
141. Kawato Y, Aonuma M, Hirota Y, et al. (1991). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
142. Kim J, Coss CC, Barrett CM, et al. (2013). Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. Int J Cancer 132:1475-1485.
143. Kim SH, Kwon HC, Oh SY, et al. (2009). Prognostic value of ERCC1, thymidylate synthase, and glutathione S-Transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32:38-43.
144. King CD, Rios GR, Green MD, Tephly TR. (2000). UDP-glucuronosyltransferases. Curr Drug Metab 1:143-161.
145. Kiss I, Sandor J, Pajkos G, et al. (2000). Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-Transferase M1 enzymes. Anticancer Res 20:519-522.
146. Kitada M, Kamataki T, Itahashi K, et al. (1985). Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch Biochem Biophys 241:275-280.
147. Kivisto KT, Kroemer HK, Eichelbaum M. (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 40:523-530.
148. Kiyohara C. (2000). Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. J Epidemiol 10:349-360.
149. Klein K, Zanger UM. (2013). Pharmacogenomics of cytochrome P450 3A4: Recent progress toward the missing heritability problem. Front Genet 4:12.
150. Klose TS, Blaisdell JA, Goldstein JA. (1999). Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295.
151. Klotz U, Hoensch H, Schuetz T, et al. (1998). Expression of intestinal drug-metabolising enzymes in patients with chronic inflammatory bowel disease. Curr Therapeut Res 59:556-563.
152. Kroemer HK, Eichelbaum M. (1995). Its the genes, stupid. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298.
153. Kuehl GE, Bigler J, Potter JD, Lampe JW. (2006). Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos 34: 199-202.
154. Kumarakulasingham M, Rooney PH, Dundas SR, et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin Cancer Res 11:3758-3765.
155. Laborde E. (2010). Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17:1373-1380.
156. Lafuente A, Pujol F, Carretero P, et al. (1993). Human glutathione S-Transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 68: 49-54.
157. Lampe JW, Chen C, Li S, et al. (2000). Modulation of human glutathione S-Transferases by botanically defined vegetable diets. Cancer Epidemiol Biomarkers Prev 9:787-793.
158. Lanza DL, Code E, Crespi CL, et al. (1999). Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells. Drug Metab Dispos 27:798-803.
159. Lanza DL, Yost GS. (2001). Selective dehydrogenation/oxygenation of 3-methylindole by cytochrome p450 enzymes. Drug Metab Dispos 29: 950-953.
160. Lee CR, Goldstein JA, Pieper JA. (2002). Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263.
161. Leskela S, Honrado E, Montero-Conde C, et al. (2007). Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer 14:645-654.
162. Lilla C, Verla-Tebit E, Risch A, et al. (2006). Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 15:99-107.
163. Linder MW, Prough RA, Valdes Jr R. (1997). Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency. Clin Chem 43: 254-266.
164. Mackenzie PI, Bock KW, Burchell B, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
165. Mannervik B, Board PG, Hayes JD, et al. (2005). Nomenclature for mammalian soluble glutathione transferases. Methods Enzymol 401: 1-8.
166. Matsuda Y, Saoo K, Yamakawa K, et al. (2007). Overexpression of CYP2A6 in human colorectal tumors. Cancer Sci 98:1582-1585.
167. Mccarroll SA, Hadnott TN, Perry GH, et al. (2006). Common deletion polymorphisms in the human genome. Nat Genet 38:86-92.
168. McIlwain CC, Townsend DM, Tew KD. (2006). Glutathione S-Transferase polymorphisms: Cancer incidence and therapy. Oncogene 25: 1639-1648.
169. Mega JL, Close SL, Wiviott SD, et al. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
170. Mercurio MG, Shiff SJ, Galbraith RA, Sassa S. (1995). Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochem Biophys Res Commun 210:350-355.
171. Meyer UA. (1996). Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 24:449-459.
172. Miles JS, Mclaren AW, Forrester LM, et al. (1990). Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371.
173. Miners JO, Mackenzie PI, Knights KM. (2010). The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42: 196-208.
174. Moorghen M, Cairns J, Forrester LM, et al. (1991). Enhanced expression of glutathione S-Transferases in colorectal carcinoma compared to non-neoplastic mucosa. Carcinogenesis 12:13-17.
175. Morel F, Fardel O, Meyer DJ, et al. (1993). Preferential increase of glutathione S-Transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones. Cancer Res 53:231-234.
176. Morel F, Rauch C, Coles B, et al. (2002). The human glutathione transferase alpha locus: Genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 12:277-286.
177. Moreno V, Glatt H, Guino E, et al. (2005). Polymorphisms in sulfotransferases SULT1A1 and SULT1A2 are not related to colorectal cancer. Int J Cancer 113:683-686.
178. Moscow JA, Fairchild CR, Madden MJ, et al. (1989). Expression of anionic glutathione-S-Transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49:1422-1428.
179. Mulder TP, Court DA, Peters WH. (1999). Variability of glutathione S-Transferase alpha in human liver and plasma. Clin Chem 45: 355-359.
180. Mulder TP, Verspaget HW, Sier CF, et al. (1995). Glutathione S-Transferase pi in colorectal tumors is predictive for overall survival. Cancer Res 55:2696-2702.
181. Murray GI, Melvin WT, Greenlee WF, Burke MD. (2001). Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41:297-316.
182. Murray GI, Taylor MC, Mcfadyen MC, et al. (1997). Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026-3031.
183. Nagar S, Zalatoris JJ, Blanchard RL. (2004). Human UGT1A6 pharmacogenetics: Identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14: 487-499.
184. Naidu KA, Nasir A, Pinkas H, et al. (2003). Glutathione-S-Transferase pi expression and activity is increased in colonic neoplasia. In Vivo 17: 479-482.
185. Nakajima M, Yamamoto T, Nunoya K, et al. (1996). Characterization of CYP2A6 involved in 30-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010-1015.
186. Nakajima M, Yamamoto T, Nunoya K, et al. (1996). Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
187. Nakamura A, Nakajima M, Yamanaka H, et al. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
188. Nakamura K, Yoshihara S, Shimada T, Guengerich FP. (1999). Selection and characterization of human cytochrome P450 1B1 mutants by random mutagenesis. ISSX Proceedings of the 9th North American ISSX Meeting, Nashville, TN, vol. 15, p. 62.
189. Nebert DW, Jones JE. (1989). Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int J Biochem 21:243-252.
190. Nelson DR, Koymans L, Kamataki T, et al. (1996). P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
191. Nhamburo PT, Kimura S, Mcbride OW, et al. (1990). The human CYP2F gene subfamily: Identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29:5491-5499.
192. Nichols WK, Mehta R, Skordos K, et al. (2003). 3-Methylindole-induced toxicity to human bronchial epithelial cell lines. Toxicol Sci 71: 229-236.
193. Nijhoff WA, Grubben MJ, Nagengast FM, et al. (1995). Effects of consumption of Brussels sprouts on intestinal and lymphocytic glutathione S-Transferases in humans. Carcinogenesis 16: 2125-2128.
194. Nijhoff WA, Mulder TP, Verhagen H, et al. (1995). Effects of consumption of brussels sprouts on plasma and urinary glutathione S-Transferase class-Alpha and-pi in humans. Carcinogenesis 16: 955-957.
195. Nishida CR, Lee M, De Montellano PR. (2010). Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78:497-502.
196. Nothlings U, Yamamoto JF, Wilkens LR, et al. (2009). Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 18:2098-2106.
197. Nowell S, Coles B, Sinha R, et al. (2002). Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: Contribution of metabolic variation to risk. Mutat Res 506-507:175-185.
198. O'Dwyer PJ, Szarka CE, Yao KS, et al. (1996). Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 98:1210-1217.
199. Oakley A. (2011). Glutathione transferases: A structural perspective. Drug Metab Rev 43:138-151.
200. Ognjanovic S, Yamamoto J, Maskarinec G, Le Marchand L. (2006). NAT2, meat consumption and colorectal cancer incidence: An ecological study among 27 countries. Cancer Causes Control 17: 1175-1182.
201. Olson KC, Dellinger RW, Zhong Q, et al. (2009). Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Drug Metab Dispos 37: 1999-2007.
202. Orzechowski A, Schrenk D, Bock-Hennig BS, Bock KW. (1994). Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyltransferase of the UGT1 gene complex. Carcinogenesis 15:1549-1553.
203. Oyama T, Kagawa N, Kunugita N, et al. (2004). Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9:1967-1976.
204. Patana AS, Kurkela M, Finel M, Goldman A. (2008). Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases. Protein Eng Des Sel 21: 537-543.
205. Patterson LH, Murray GI. (2002). Tumour cytochrome P450 and drug activation. Curr Pharm Des 8:1335-1347.
206. Pavek P, Dvorak Z. (2008). Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9: 129-143.
207. Pearson WR, Vorachek WR, Xu SJ, et al. (1993). Identification of classmu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet 53:220-233.
208. Pelkonen O, Raunio H. (1995). Individual expression of carcinogenmetabolizing enzymes: Cytochrome P4502A. J Occup Environ Med 37:19-24.
209. Peng CT, Chen JC, Yeh KT, et al. (2003). The relationship among the polymorphisms of SULT1A1, 1A2 and different types of cancers in Taiwanese. Int J Mol Med 11:85-89.
210. Peters WH, Kock L, Nagengast FM, Kremers PG. (1991). Biotransformation enzymes in human intestine: Critical low levels in the colon?. Gut 32:408-412.
211. Peters WH, Nagengast FM, Wobbes T. (1989). Glutathione S-Transferases in normal and cancerous human colon tissue. Carcinogenesis 10: 2371-2374.
212. Peters WH, Roelofs HM. (1992). Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: A possible role for glutathione S-Transferases. Cancer Res 52:1886-1890.
213. Peters WH, Roelofs HM, Hectors MP, et al. (1993). Glutathione and glutathione S-Transferases in Barrett's epithelium. Br J Cancer 67: 1413-1417.
214. Pfohl-Leszkowicz A, Grosse Y, Carriere V, et al. (1995). High levels of DNA adducts in human colon are associated with colorectal cancer. Cancer Res 55:5611-5616.
215. Plewka D, Plewka A, Szczepanik T, et al. (2014). Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions. Pathol Res Pract 210: 242-249.
216. Potter GA, Patterson LH, Wanogho E, et al. (2002). The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86:774-778.
217. Quattrochi LC, Tukey RH. (1989). The human cytochrome Cyp1A2 gene contains regulatory elements responsive to 3-methylcholanthrene. Mol Pharmacol 36:66-71.
218. Ranganathan S, Tew KD. (1991). Immunohistochemical localization of glutathione S-Transferases alpha, mu, and pi in normal tissue and carcinomas from human colon. Carcinogenesis 12: 2383-2387.
219. Rendic S, Guengerich FP. (2012). Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316-1383.
220. Rieger MA, Ebner R, Bell DR, et al. (2004). Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 64:2357-2364.
221. Ross VL, Board PG, Webb GC. (1993). Chromosomal mapping of the human Mu class glutathione S-Transferases to 1p13. Genomics 18: 87-91.
222. Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
223. Rothwell PM, Price JF, Fowkes FG, et al. (2012). Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602-1612.
224. Rothwell PM, Wilson M, Elwin CE, et al. (2010). Long-Term effect of aspirin on colorectal cancer incidence and mortality: 20-Year followup of five randomised trials. Lancet 376:1741-1750.
225. Sachse C, Smith G, Wilkie MJ, et al. (2002). A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23:1839-1849.
226. Salonpaa P, Hakkola J, Pasanen M, et al. (1993). Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. Eur J Pharmacol 248:95-102.
227. Samowitz WS, Wolff RK, Curtin K, et al. (2006). Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 4:894-901.
228. Schuetz JD, Beach DL, Guzelian PS. (1994). Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
229. Sheehan D, Meade G, Foley VM, Dowd CA. (2001). Structure, function and evolution of glutathione transferases: Implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J 360:1-16.
230. Shimada T, Yamazaki H, Mimura M, et al. (1996). Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515-522.
231. Shou M, Korzekwa KR, Krausz KW, et al. (1996). Specificity of cDNAexpressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7, 12-dimethylbenz[a]anthracene. Mol Carcinog 17:241-249.
232. Smith TJ, Stoner GD, Yang CS. (1995). Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res 55:5566-5573.
233. Sorensen M, Autrup H, Olsen A, et al. (2008). Prospective study of NAT1 and NAT2 polymorphisms, tobacco smoking and meat consumption and risk of colorectal cancer. Cancer Lett 266:186-193.
234. Stenstedt K, Hallstrom M, Johansson I, et al. (2012). The expression of CYP2W1: A prognostic marker in colon cancer. Anticancer Res 32: 3869-3874.
235. Stiborova M, Borek-Dohalska L, Hodek P, et al. (2002). New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 403:41-49.
236. Stiborova M, Martinek V, Rydlova H, et al. (2002). Sudan I is a potential carcinogen for humans: Evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res 62:5678-5684.
237. Stiborova M, Martinek V, Rydlova H, et al. (2005). Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett 220:145-154.
238. Strange RC, Fryer AA. (1999). The glutathione S-Transferases: Influence of polymorphism on cancer susceptibility. IARC Sci Publ 148:231-249.
239. Strange RC, Matharoo B, Faulder GC, et al. (1991). The human glutathione S-Transferases: A case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma. Carcinogenesis 12:25-28.
240. Strassburg CP, Manns MP, Tukey RH. (1997). Differential downregulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57: 2979-2985.
241. Strassburg CP, Nguyen N, Manns MP, Tukey RH. (1998). Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 54:647-654.
242. Strassburg CP, Nguyen N, Manns MP, Tukey RH. (1999). UDPglucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
243. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. (1997). Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
244. Strassburg CP, Vogel A, Kneip S, et al. (2002). Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50:851-856.
245. Stresser DM, Kupfer D. (1999). Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
246. Su T, Sheng JJ, Lipinskas TW, Ding X. (1996). Expression of CYP2A genes in rodent and human nasal mucosa. Drug Metab Dispos 24: 884-890.
247. Sutoh I, Kohno H, Nakashima Y, et al. (2000). Concurrent expressions of metallothionein, glutathione S-Transferase-pi, and P-glycoprotein in colorectal cancers. Dis Colon Rectum 43:221-232.
248. Swanson C, Mellstrom D, Lorentzon M, et al. (2007). The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab 92:4878-4882.
249. Taioli E, Flores-Obando RE, Agalliu I, et al. (2011). Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis 32:1361-1365.
250. Tan KL, Jankova L, Chan C, et al. (2011). Clinicopathological correlates and prognostic significance of glutathione S-Transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology 59:1057-1070.
251. Tan Z, Feng M, Luo Y, et al. (2013). GSTP1 Ile105Val polymorphism and colorectal cancer risk: An updated analysis. Gene 527:275-282.
252. Tang J, Cao Y, Rose RL, et al. (2001). Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos 29:1201-1204.
253. Tang J, Cao Y, Rose RL, Hodgson E. (2002). In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem Biol Interact 141:229-241.
254. Teh LK, Bertilsson L. (2012). Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 27:55-67.
255. Thorn M, Finnstrom N, Lundgren S, et al. (2005). Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54-60.
256. Tiemersma EW, Bunschoten A, Kok FJ, et al. (2004). Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. Int J Cancer 108:97-103.
257. Tiemersma EW, Kampman E, Bueno De Mesquita HB, et al. (2002). Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: Results from a Dutch prospective study. Cancer Causes Control 13:383-393.
258. Tiemersma EW, Voskuil DW, Bunschoten A, et al. (2004). Risk of colorectal adenomas in relation to meat consumption, meat preparation, and genetic susceptibility in a Dutch population. Cancer Causes Control 15:225-236.
259. Townsend DM, Tew KD. (2003). The role of glutathione-S-Transferase in anti-cancer drug resistance. Oncogene 22:7369-7375.
260. Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
261. Tukey RH, Strassburg CP, Mackenzie PI. (2002). Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62:446-450.
262. Umemoto A, Kajikawa A, Tanaka M, et al. (1994). Presence of mucosaspecific DNA adduct in human colon: Possible implication for colorectal cancer. Carcinogenesis 15:901-905.
263. Usmani KA, Rose RL, Goldstein JA, et al. (2002). In vitro human metabolism and interactions of repellent N, N-diethyl-m-Toluamide. Drug Metab Dispos 30:289-294.
264. Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, et al. (2007). RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res 27:4443-4450.
265. Van Der Logt EM, Bergevoet SM, Roelofs HM, et al. (2004). Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-Transferases and colorectal cancer risk. Carcinogenesis 25: 2407-2415.
266. Van Lieshout EM, Peters WH, Jansen JB. (1996). Effect of oltipraz, alpha-Tocopherol, beta-carotene and phenethylisothiocyanate on rat oesophageal, gastric, colonic and hepatic glutathione, glutathione S-Transferase and peroxidase. Carcinogenesis 17:1439-1445.
267. Van Poppel G, De Vogel N, Van Balderen PJ, Kok FJ. (1992). Increased cytogenetic damage in smokers deficient in glutathione S-Transferase isozyme mu. Carcinogenesis 13:303-305.
268. Verhulst ML, Van Oijen AH, Roelofs HM, et al. (2000). Antral glutathione concentration and glutathione S-Transferase activity in patients with and without Helicobacter pylori. Dig Dis Sci 45: 629-632.
269. Vlaykova TGM, Yovchev Y, Dimov D, et al. (2012). Glutathione-Stransferases in development, progression and therapy of colorectal cancer. Chapter 5. In: Ettarh DR, ed. Colorectal cancer biology-From genes to tumor. Rijeka, Croatia: InTech, 81-106.
270. Wahab PJ, Peters WH, Roelofs HM, Jansen JB. (2001). Glutathione Stransferases in small intestinal mucosa of patients with coeliac disease. Jpn J Cancer Res 92:279-284.
271. Wang D, Dubois RN. (2012). Epoxyeicosatrienoic acids: A double-edged sword in cardiovascular diseases and cancer. J Clin Invest 122:19-22.
272. Wang H, Lanza DL, Yost GS. (1998). Cloning and expression of CYP2F3, a cytochrome P450 that bioactivates the selective pneumotoxins 3-methylindole and naphthalene. Arch Biochem Biophys 349: 329-340.
273. Wang H, Yamamoto JF, Caberto C, et al. (2011). Genetic variation in the bioactivation pathway for polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal neoplasia. Carcinogenesis 32: 203-209.
274. Wang M, Qi YY, Chen S, et al. (2012). Expression of UDPglucuronosyltransferase 1A, nuclear factor erythroid-E2-related factor 2 and Kelch-like ECH-Associated protein 1 in colonic mucosa, adenoma and adenocarcinoma tissue. Oncol Lett 4:925-930.
275. Wang M, Sun DF, Wang S, et al. (2013). Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer. PLoS One 8:e57045.
276. Wark PA, Grubben MJ, Peters WH, et al. (2004). Habitual consumption of fruits and vegetables: Associations with human rectal glutathione S-Transferase. Carcinogenesis 25:2135-2142.
277. Welfare MR, Cooper J, Bassendine MF, Daly AK. (1997). Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 18:1351-1354.
278. Westlind A, Malmebo S, Johansson I, et al. (2001). Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281: 1349-1355.
279. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. (1995). Gene deletion of glutathione S-Transferase theta: Correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 4:253-259.
280. Williams JA, Ring BJ, Cantrell VE, et al. (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
281. Wong CF, Liyou N, Leggett B, et al. (2002). Association of the SULT1A1 R213H polymorphism with colorectal cancer. Clin Exp Pharmacol Physiol 29:754-758.
282. Wu ZL, Sohl CD, Shimada T, Guengerich FP. (2006). Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 69:2007-2014.
283. Xiao J, Zheng Y, Zhou Y, et al. (2014). Sulfotransferase SULT1A1 Arg213His polymorphism with cancer risk: A meta-Analysis of 53 case-control studies. PLoS One 9:e106774.
284. Xie HG, Wood AJ, Kim RB, et al. (2004). Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5: 243-272.
285. Xu S, Wang Y, Roe B, Pearson WR. (1998). Characterization of the human class Mu glutathione S-Transferase gene cluster and the GSTM1 deletion. J Biol Chem 273:3517-3527.
286. Yamano S, Tatsuno J, Gonzalez FJ. (1990). The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322-1329.
287. Ye Z, Parry JM. (2003). A meta-Analysis of 20 case-control studies of the glutathione S-Transferase M1 (GSTM1) status and colorectal cancer risk. Med Sci Monit 9:SR83-SR91.
288. Yengi LG, Xiang Q, Pan J, et al. (2003). Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 316:103-110.
289. Yun CH, Shimada T, Guengerich FP. (1991). Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40:679-685.
290. Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.
291. Zanger UM, Turpeinen M, Klein K, Schwab M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.
292. Zeldin DC, Dubois RN, Falck JR, Capdevila JH. (1995). Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322:76-86.
293. Zeldin DC, Moomaw CR, Jesse N, et al. (1996). Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 330:87-96.
294. Zhang ZJ, Hao K, Shi R, et al. (2011). Glutathione S-Transferase M1 (GSTM1) and glutathione S-Transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: A HuGE review and meta-Analysis. Am J Epidemiol 173:847-857.
295. Zhou SF, Chan E, Zhou ZW, et al. (2009). Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab 10:713-729.
296. Zhou SF, Wang B, Yang LP, Liu JP. (2010). Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 42:268-354.